Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder

AIMS AND OBJECTIVES: The incidence of bladder malignancy is increasing worldwide and the projected rise is 28% by 2010 for both sexes (WHO). Though intravesical adjuvant therapy with BCG is superior to any other immunotherapeutic/chemotherapeutic agent in reducing tumor recurrences and disease progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohanty, N. K., Nayak, Rajiba L., Vasudeva, Pawan, Arora, R. P.
Formato: Texto
Lenguaje:English
Publicado: Medknow Publications 2008
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684230/
https://www.ncbi.nlm.nih.gov/pubmed/19468358
http://dx.doi.org/10.4103/0970-1591.35759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684230/
https://www.ncbi.nlm.nih.gov/pubmed/19468358
http://dx.doi.org/10.4103/0970-1591.35759

Ejemplares similares